Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$27.2 million.

  • Northwest Biotherapeutics' Net Income towards Common Stockholders fell 3935.2% to -$27.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$91.2 million, marking a year-over-year decrease of 2845.92%. This contributed to the annual value of -$85.2 million for FY2024, which is 3234.12% down from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Net Income towards Common Stockholders of -$27.2 million as of Q3 2025, which was down 3935.2% from -$15.9 million recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year Net Income towards Common Stockholders high stood at $213.9 million for Q4 2021, and its period low was -$32.9 million during Q3 2022.
  • For the 5-year period, Northwest Biotherapeutics' Net Income towards Common Stockholders averaged around -$7.0 million, with its median value being -$18.3 million (2024).
  • Over the last 5 years, Northwest Biotherapeutics' Net Income towards Common Stockholders had its largest YoY gain of 17631.21% in 2021, and its largest YoY loss of 25700.69% in 2021.
  • Over the past 5 years, Northwest Biotherapeutics' Net Income towards Common Stockholders (Quarter) stood at $213.9 million in 2021, then tumbled by 113.23% to -$28.3 million in 2022, then soared by 49.4% to -$14.3 million in 2023, then plummeted by 99.02% to -$28.5 million in 2024, then increased by 4.61% to -$27.2 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$27.2 million for Q3 2025, versus -$15.9 million for Q2 2025 and -$19.6 million for Q1 2025.